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Abstract 
Background: Ulcerative colitis (UC) is a highly progressive inflammatory disease that requires the interaction of 
epithelial, immune, endothelial and muscle cells and fibroblasts. Previous studies suggested two inflammatory condi-
tions in UC-patients: ‘acute’ and ‘remodeling’ and that the design of a disease network might improve the understand-
ing of the inflammatory processes. The objective of the study was to design and validate a disease network in the 
NOD-SCID IL2rγnull (NSG)-UC mouse model to get a better understanding of the inflammatory processes.
Methods: Leukocytes were isolated from the spleen of NSG-UC mice and subjected to flow cytometric analysis. 
RT-PCR and RNAseq analysis were performed from distal parts of the colon. Based on these analyses and the effects of 
interleukins, chemokines and growth factors described in the literature, a disease network was designed. To validate 
the disease network the effect of infliximab and pitrakinra was tested in the NSG-UC model. A clinical- and histologi-
cal score, frequencies of human leukocytes isolated from spleen and mRNA expression levels from distal parts of the 
colon were determined.
Results: Analysis of leukocytes isolated from the spleen of challenged NSG-UC mice corroborated CD64, CD163 and 
CD1a expressing CD14+ monocytes, CD1a expressing CD11b+ macrophages and HGF, TARC, IFNγ and TGFß1 mRNA 
as inflammatory markers. The disease network suggested that a proinflammatory condition elicited by IL-17c and 
lipids and relayed by cytotoxic T-cells, Th17 cells and CD1a expressing macrophages and monocytes. Conversely, the 
remodeling condition was evoked by IL-34 and TARC and promoted by Th2 cells and M2 monocytes. Mice benefitted 
from treatment with infliximab as indicated by the histological- and clinical score. As predicted by the disease network 
infliximab reduced the proinflammatory response by suppressing M1 monocytes and CD1a expressing monocytes 
and macrophages and decreased levels of IFNγ, TARC and HGF mRNA. As predicted by the disease network inflamma-
tion aggravated in the presence of pitrakinra as indicated by the clinical and histological score, elevated frequencies 
of CD1a expressing macrophages and TNFα and IFNγ mRNA levels.
Conclusions: The combination of the disease network and the NSG-UC animal model might be developed into a 
powerful tool to predict efficacy or in-efficacy and potential mechanistic side effects.
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Background
Inflammation in ulcerative colitis (UC) is a highly 
dynamic, spatial and temporal response and involves the 
communication of epithelial-, immune-, endothelial- and 
muscle cells and fibroblasts [1]. In contrast to Crohn’s dis-
ease, UC is considered a Th2 characterized inflammation. 
However, the role of Th2 cytokines has not been conclu-
sively demonstrated [2, 3]. To get a better understanding 
of the processes in UC, we took on a different approach 
and considered the Th2 arm as the driver of wound heal-
ing ultimately leading to remodeling of the colon archi-
tecture [1, 4]. Based on the assumption that epithelial 
cells play an active role in the inflammatory process 
by releasing cytokines to direct immune responses we 
designed a panel of immune cells, cytokines and growth 
factors to develop immune profiles of UC patients. This 
profiling led to the identification of two inflammatory 
conditions referred to as ‘acute’ and ‘remodeling’, the lat-
ter of which was favored by treatment with infliximab [4]. 
The acute inflammatory condition was characterized by 
immune cells supporting the adaptive immunity, thymus 
and activation regulated chemokine (TARC) and hepatic 
growth factor (HGF). In contrast, the remodeling condi-
tion was characterized by innate immune cells such as 
NK T cells and TSLPR expressing CD14+ monocytes, 
periostin and transforming growth factor (TGF) ß1. The 
observation of an acute inflammatory arm was corrobo-
rated by data showing elevated frequencies of CD8+-, 
Th1- and Th17-T-cells in UC patients with active disease 
[5]. Furthermore, immune profiling of UC patients led 
to the identification of CD1a expressing CD11b+ mac-
rophages and CD14+ monocytes as biological markers 
for UC [4]. These cells have been shown to present self-
lipids to conventional αß CD4+ T cells to evoke an auto-
immune response [6–8]. Finally, analysis of autoantibody 
levels suggested that autoimmunity might play a crucial 
role in a subgroup of patients (our own results). Thus, 
there seems to be a strong proinflammatory response 
which might be driven by IL-17 secreted by Th17 cells 
and by Th1 cells arising from Th17 cells in the presence 
of IL-6 [9, 10] or Th1 cells activated via CD1a providing 
an explanation for the responsiveness to TNFα block-
ers of a subgroup of UC patients. All these observations 
suggested that a map of the disease network illustrating 
the interaction and communication of immune-, epithe-
lial cells and fibroblast may be a promising approach to 
understand inflammatory processes in UC and to predict 
efficacy and potential side effects of therapeutics. For the 
design and validation of the disease network, we took 
advantage of a mouse model of UC that is based on NOD-
SCID IL2rγnull (NSG) mice reconstituted with PBMC 
from human patients with UC (NSG-UC) [11]. Most of 
the cell types identified as crucial in UC patients could 
also be detected in spleen or colon of challenged mice. As 
in our previous hypothesis [1], the disease network was 
based on the assumption that damaged epithelial cells 
release signals to direct immune responses. However, we 
expanded the view and included IL-7, IL-17c, and lipids 
as factors to drive inflammation in UC. IL-7 is secreted 
by intestinal epithelial- and goblet cells to activate and to 
induce proliferation of T-cells and thus acts probably as 
an amplifier of a given immunological direction [12]. IL-
17c promotes IL-17 responses of Th17 cells and autoim-
munity [13]. IL-17A that is released by Th17 cells acts on 
epithelial cells to induce the release of IL-8 and CXCL1 
to attract neutrophils and induce mucus production [14]. 
Both, IL-17A and IL-17c act on fibroblasts to release IL-6 
[14]. In the presence of IL-6 and other factors, Treg can 
adopt a Th17 phenotype thus skipping the inflammatory 
balance twofold: by diminishing the Treg and by increas-
ing the Th17 pool [15].
IL-33 has been described as an activator of innate lym-
phoid cells [16] to induce the classical Th2 cytokines 
IL-4, IL-5, and IL-13. In turn, IL-13 impairs barrier integ-
rity and induces goblet cell hyperplasia and mucus pro-
duction [3, 17].
IL-34 that has recently been described as an important 
interleukin in IBD is thought to promote the differen-
tiation of M2 monocytes [18]. In normal wound healing 
processes, M2 macrophages are responsible for resolving 
inflammation and promoting fibrosis [19].
Thymic stromal lymphopoietin has been described as 
an important modulator of Th1/Th2 immune responses 
and to play a major role in tissue homeostasis and main-
taining peripheral tolerance [20]. In the presence of IL-4, 
TSLP instructs dendritic cells to enforce a Th2 phenotype 
in naïve T-cells ultimately resulting in remodeling of the 
colon architecture [21–23]. In concert with IL-13 TSLP 
induces the differentiation of M2 monocytes [24] and 
fibrocytes [25] which evokes an immune modulatory and 
remodeling response by the secretion of TGFß1, IL-10, 
and periostin. TARC activates and attracts leukocytes 
bearing the CCR4 receptor to include Th2-, Th17-cells, 
and monocytes [26–28]. Recently it has been shown to 
signify effector-type FoxP3+ CD4+ regulatory T cells. 
Depletion of these cells with an anti CCR4 antibody 
evoked anti-tumor responses in humans [29].
Immune profiling of patients had previously identified 
CD1a expressing macrophages or monocytes as biomark-
ers to distinguish between UC patients and Non-UC 
donors [4]. CD1a has been known for decades as a phe-
notypic marker of human epidermal Langerhans cells. 
Like other members of the CD1 family, CD1a presents 
lipids to evoke T cell activation resulting in the release 
of IL-22, IL-13 and IFNy [8, 30]. IL-22 promotes wound 
healing by inducing epithelial hyperplasia [31]. CD1a 
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macrophages activate conventional αß CD4+ T cells. 
Furthermore, CD1a expressing monocytes have been 
shown to be widely distributed in other organs includ-
ing the colon and have been shown to express IL-12 
and to activate Th1 cells [7, 32]. The supply of fatty acid 
ligands could be provided by phospholipase A2 (PLA2)—
an major ingredient of inflammation and bee- and wasp 
venom [33].
The map of the disease network was validated by treat-
ing NSG-UC mice with therapeutics interfering with the 
‘acute’ or ‘remodeling’ inflammatory condition. Results 
confirmed the previously suggested two inflammatory 
conditions and indicated that the disease map might be 
developed into a useful tool to predict efficacy of thera-
peutics and their potential mechanistic side effects.
Methods
Isolation of PBMC and engraftment
60  ml of peripheral blood were collected from the arm 
vein of patients suffering from UC in trisodium citrate 
solution (S-Monovette, Sarstedt, Nürnberg, Germany). 
Hank’s balanced salt solution (HBSS, Sigma Aldrich, 
Deisenhofen, Germany) was used to dilute the blood in 
a 1:2 ratio and 30 ml of the suspension were loaded onto 
LeucoSep tubes (Greiner Bio One, Frickenhausen, Ger-
many). Peripheral blood mononuclear cells (PBMC) were 
separated by centrifugation at 400g for 30  min and no 
deceleration. The interphase was extracted and diluted 
with phosphate buffered saline (PBS) to a final volume of 
40  ml. Cells were counted and centrifuged at 1400g for 
5 min. The cell pellet was resuspended in PBS at a con-
centration of 4 × 106 cells in 100 µl.
Six to eight-week old NOD.cg-PrkdcSCID  Il2rgtm1Wjl/
Szj mice (abbreviated as NOD IL-2Rγnull) were engrafted 
with 100 µl cell suspension into the tail vein on day 1.
Animal study protocol
NOD IL-2Rγnull mice were obtained from Charles River 
Laboratories (Sulzfeld, Germany). Mice were kept under 
specific pathogen-free conditions in individually ven-
tilated cages in a facility controlled according to the 
Federation of Laboratory Animal Science Association 
(FELASA) guidelines. Following engraftment (day 1) 
mice were pre-sensitized by rectal application of 150 µl of 
10% ethanol on day 8 using a 1 mm cat catheter (Henry 
Schein, Hamburg, Germany). The catheter was lubricated 
with Xylocaine©Gel 2% (AstraZeneca, Wedel). The rec-
tal application was performed under general anesthe-
sia using 4% isoflurane. Post application mice were kept 
at an angle of 30° to avoid ethanol dripping. On day 15 
and 18 mice were challenged by rectal application of 50% 
ethanol following the protocol of day 8. Mice were sacri-
ficed on day 21. Pitrakinra (10 µg in 0.5% Methylcellulose, 
0.05% TWEEN 80 in PBS) [34] was applied on day 7–9 
and 14–21. Sterile Saline (B. Braun Melsungen AG, Ger-
many) served as a control. Infliximab, [6  mg/kg (Remi-
cade©, Janssen The Netherlands)] and isotype control 
(30 µg in 200 µl PBS, Morphosys AG, Planegg, Germany) 
were applied on day 7 and 14. All treatments were applied 
intraperitoneally.
Clinical activity score
The assessment of colitis-severity was performed daily 
according to the following scoring system: Loss of body 
weight: 0% (0), 0–5% (1), 5–10% (2), 10–15% (3), 15–20% 
(4). Stool consistency: formed pellet (0), loose stool or 
unformed pellet (2), liquid stools (4). Behavior: normal 
(0), reduced activity (1), apathy (4) and ruffled fur (1). 
Body posture: intermediately hunched posture (1), per-
manently hunched posture (2). The scores were added 
daily into a total score with a maximum of 12 points per 
day. Animals who suffered from weight loss > 20%, rec-
tal bleeding, rectal prolapse, self-isolation or a severity 
score  >  7 were euthanized immediately and not taken 
into count. All scores were added for statistical analysis.
Isolation of human leukocytes
To isolate human leukocytes from murine spleen, spleens 
were minced and cells filtrated through a 70  µl cell 
strainer (Greiner Bio-One, Frickenhausen) followed by 
centrifugation at 1400g for 5  min and resuspended in 
FACS buffer (1× PBS, 2 mM EDTA, 2% FCS). For further 
purification cell suspensions were filtrated using a 35 µm 
cell strainer (Greiner Bio-One, Frickenhausen) and then 
labeled for flow cytometry analysis. Cells were defined as 
shown in Additional file 1: Table S1.
Flow cytometry analysis
Labeling of human leukocytes was performed accord-
ing to Additional file  1: Table S2. All antibodies were 
purchased from Biolegend (San Diego, USA) and used 
according to the manufacturer’s instructions. Flow 
cytometry was performed using a BD FACS Canto II™ 
and analysed with FlowJo 10.1-Software (FlowJo LLC, 
Oregon, USA).
Histological analysis
Samples from distal parts of the colon were fixed in 4% 
formaldehyde for 24  h, before storage in 70% ethanol 
and were routinely embedded in paraffin. Samples were 
cut into 3  µm sections and stained with haematoxylin 
and eosin (H&E). Epithelial erosions were scored as fol-
lows: no lesions (0), focal lesions (1), multifocal lesions 
(2), major damage with the involvement of basal mem-
brane (3). Inflammation was scored as follows: infiltra-
tion of few inflammatory cells into the lamina propria (1), 
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major infiltration of inflammatory cells into the Lamina 
propria (2), confluent infiltration of inflammatory cells 
into the Lamina propria (3), infiltration of inflammatory 
cells including tunica muscularis (4). Fibrosis was scored 
as follows: focal fibrosis (1), multifocal fibrosis and crypt 
atrophy (2). The presence of edema, hyperemia and crypt 
abscess was scored with one additional point in each 
case. The scores for each criterion were added into a total 
score ranging from 0 to 12. Images were taken with a 
Zeiss AxioVert 40 CFL camera. Figures show representa-
tive longitudinal sections in original magnification. In 
Adobe Photoshop CS6 a tonal correction was applied to 
enhance contrasts within the pictures.
RNA analysis
RNA extraction and cDNA synthesis
Approximately 1  cm from distal parts of the colon was 
homogenized by using a TissueLyser LT (Qiagen, Hilden, 
Germany) and total RNA was extracted according to the 
manufacturer’s instruction using RNeasy Plus Universal 
Mini Kit (Qiagen, Hilden, Germany) and Chloroform 
(Sigma-Aldrich, St. Louis, MO, USA). No further treat-
ment with DNase was needed since gDNA Eliminator 
Solution was included in the kit.
Five microgram of total RNA were used for cDNA 
synthesis. Reverse transcription was performed using a 
Mastercycler gradient (Eppendorf, Hamburg, Germany) 
using QuantiNova Reverse Transcription Kit (Qiagen, 
Hilden, Germany). Between 10 pg and 100 ng were used 
according to the TaqMan Fast Advanced Master Mix 
protocol (Thermo Fisher Scientific, Waltham, MA, USA).
RNA and cDNA purity determined by Nanodrop 2000 
spectrophotometry (Thermo Fisher Scientific, Waltham, 
MA, USA).
Quantitative real‑time PCR
Quantitative real-time PCR was performed accord-
ing to the TaqMan Fast Advanced Master Mix proto-
col (Thermo Fisher Scientific, Waltham, MA, USA) 
according to the Applied Biosystems StepOnePlus real-
time PCR system (Thermo Fisher Scientific, Waltham, 
MA, USA). included The following primers were used: 
The housekeeping genes GAPDH (Mm99999915_
g1) and GUSB (Mm00446953_m1) as well as TGFβ 
(Mm01178820_m1), HGF (Hs04329698_m1), CCL17 
(Mm01244826_g1), IFNγ (Hs00989291_m1) and TNFα 
(HS01113624_g1) (Single Tube TaqMan Gene Expression 
Assays, Thermo Fisher Scientific, Waltham, MA, USA). 
The analysis was performed using StepOnePlus™ Soft-
ware v2.3.
The mean cycle threshold (CT) value was calculated for 
the housekeeping genes. Relative expression values for 
the analyzed genes were then calculated as the difference 
between the mean cycle threshold (CT) of the house-
keeping genes and the analyzed gene (delta CT) and 
depicted as the logarithmic value.
RNAseq analysis
RNAseq and bioinformatic analyses were performed by 
IMGM Laboratories GmbH, Martinsried, Germany. RNA 
sequencing was performed on the Illumina TruSeq  500 
next generations sequencing system and its high output 
mode with 1 × 75 bp single-end read chemistry. For all 
samples, the most recent mouse reference genome (mus 
musculus GRCm38.p3 C57BL/6, source: NCBI) as well 
as the most recent human reference genome hg19 (homo 
sapiens, GRCh 37.p5, source NCBI) were combined and 
used as reference sequence for mapping. Expression val-
ues were processed to total exon read count/mapped 
reads [million] * exon length [kb] (RPKM). The compari-
son of the control versus ethanol challenged group was 
based on the ‘total exon reads’ expression values and was 
analyzed statistically by the CLC Genomics Workbench 
tool ‘empirical analysis of DGE (EDGE)’. For comparison 
of the groups, the ‘Exact Test’ was used.
For analyzing differences in expression value of mouse 
genes a feature was classified as induced/repressed in a 
specific comparison if its FDR-corrected p value is ≤ 0.05 
and if it has a fold change value ≥ 2/≤ 2.
For analyzing differences in expression value of human 
genes, a feature is classified as induced/repressed in a 
specific comparison if its non-corrected p value is ≤ 0.05.
Statistics
Statistical analysis was performed with R: a language and 
environment for statistical computing (R Foundation 
for Statistical Computing, Vienna, Austria. URL https://
www.R-project.org/) and BRB Array Tools (https://brb.
nci.nih.gov/BRB-ArrayTools/). Variables were repre-
sented with mean, standard deviation, median, and IQR 
values. To compare binary groups A two-sided Student’s t 
test and a confidence level = 0.95 was used. If more than, 
two groups were analyzed ANOVA followed by Tukey 
HSD was conducted. Spearman correlation analysis was 
performed.
Results
Challenge with ethanol predominantly affects monocytes 
and macrophages in the NSG‑UC mouse model
To identify cellular and molecular markers that were cor-
related with inflammation in the NSG-UC mouse model 
experiments were repeated with eight different donors 
(Table 1). NSG mice were reconstituted with PBMC and 
challenged according to a standard protocol as described 
in “Methods”. Eight days post reconstitution the mice 
were divided into two groups: one was left unchallenged, 
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the other was challenged by rectal application of ethanol. 
The groups contained four to six animals. Upon challenge 
with ethanol mice stools became soft or liquid, the ani-
mals lost weight, and the activity was reduced. Control 
animals displayed hardly any symptoms. Symptoms were 
classified according to a clinical score described in “Meth-
ods”. Upon challenge, the clinical score increased sig-
nificantly (Fig. 1C), (for complete data set see Additional 
file  1: Table S3). Macroscopic inspection of colons cor-
roborated the data obtained from analyzing the clinical 
Table 1 Patient baseline characteristics
Donor Treatment SCCAI Age Gender Time since diagnosis
1 Infliximab, glucocorticoid, mesalazine 5 36 w 12
2 No 10 52 m 21
3 No 5 52 m 21
4 Colectomy, loperamid, mesalazine, 46 w 20
5 Infliximab, glucocorticoid, mesalazine 11 36 w 12
6 Adalimumab, mesalazine 5 35 m 16
7 Infliximab 2 68 w 38
8 Adalimumab 3 53 w 13
Fig. 1 NSG mice reconstituted with PBMC from UC donors develop UC like symptoms and phenotype upon challenge with ethanol. A Macropho-
tographs of colons at autopsy of NSG-UC mice. a Unchallenged control group (control). b Group challenged with 10% ethanol at day 8, and 50% 
ethanol at days 15 and 18 (ethanol). B Photomicrographs of H&E-stained sections of distal parts of the colon from mice that had been challenged a 
control, b ethanol. Arrow indicates edema and influx of inflammatory cells. C Clinical- and histological score of control and ethanol challenged mice 
that had been challenged as described in A depicted as boxplot diagrams. Boxes represent upper and lower quartiles. Whiskers represent variability 
and outliers are plotted as individual points. Sample sizes: clinical activity score control n = 32, ethanol = 38; histological score: control n = 31, chal-
lenged n = 37. For comparison of unchallenged control group versus challenged group, a Student T-test was conducted
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score. The ethanol challenged mice were characterized by 
soft or absent pellets and dilated colons (Fig. 1A). Histo-
logical analysis revealed the influx of a mixed infiltrate of 
leukocytes, edema, crypt loss, and changes in the colon 
architecture (Fig.  1B). To further analyze the inflamma-
tion human leukocytes were isolated from the spleen and 
subjected to flow cytometric analysis. Although we would 
identify donor dependent patterns on subjects of T-cells 
and B-cells (data not shown) the most donor independ-
ent effects were observed in macrophages and monocytes 
and subtypes thereof (Fig.  2a). Thus, we would define 
CD14+ monocytes expressing CD64, CD163, CD206 or 
CD1a and CD11b+ macrophages expressing CD1a as the 
most significant cell types associated with inflammation 
in the NSG-UC model. We did not observe increased 
maturation of macrophages and monocytes as indicated 
by similar levels of CD86 expressing macrophages and 
monocytes. Effects on subsets of T-cells were donor 
dependent and could not be described as generally 
affected by challenge, however, we could observe a cor-
relation of effector memory CD8+ cells with the clinical 
activity score (rho = 0.4, p = 0.02) and with Th17 CD4+ 
T-cells (rho =  0.4, p =  0.015), indicating that both cell 
types might be involved in the development of symptoms 
and phenotype (Fig.  2b). mRNA expression analysis by 
RT PCR from RNA isolated from distal parts of the colon 
revealed that TARC, TGFß1, and HGF were the markers 
most reliably associated with inflammation. IFNγ levels 
could not be detected in all samples and displayed high 
variability (Fig. 2c).
RNA expression analysis
To gain a better understanding of the epithelial triggers 
eliciting the immunological responses in the NSG-UC 
mouse model in response to challenge with ethanol, an 
RNAseq analysis was performed with tissue samples 
isolated from distal parts of the colon. For reconstitu-
tion, a donor was selected who exhibited a simple clini-
cal activity score index (SCCAI) [35] of 5. Reconstitution 
and challenge was performed according to the standard 
protocol. Following reconstitution, mice were sepa-
rated into two groups: the control group (control) and 
the ethanol challenged group (ethanol). Each group 
contained four animals. Upon challenge with ethanol 
the ethanol group developed a clinical activity score 
of 5  ±  2.9, (mean  ±  S.D.) and a histological score of 
6.25 ± 2.2, whereas the control group developed hardly 
any symptoms and phenotype as indicated by a clini-
cal activity score of 1.5 ± 1.3 and a histological score of 
1.5 ±  0.6. Table  2 shows a selection of prominent pro-
teins whose expression was significantly changed upon 
challenge with ethanol (complete analysis will be made 
accessible online). Unexpectedly, expression of IL-33 
was decreased by a factor of almost 2, whereas expres-
sion of IL-34 was significantly increased. Expression of 
IL-17c was also increased by a factor of 11, although the 
original values were much lower as compared to IL-33 
and IL-34. Expression of TSLP was increased by a fac-
tor 1.39. As previously shown TGFß1 was elevated by a 
factor of 1.45 in response to ethanol and in this experi-
ment TNFa seemed to be a major proinflammatory 
cytokine. No expression of hIFNγ could be detected in 
this experiment a result which was also confirmed by 
RT-PCR analysis (data not shown). Unexpectedly, an 
antagonist of IL-1b, IL-1rn was significantly expressed 
and elevated in response to ethanol (fold change = 1.39). 
The inflammation induced by ethanol was also charac-
terized by the typical inflammatory markers of variants 
of phospholipases A2 Pla2g10 and Pla2g2f which were 
elevated 1.16 and 1.33 fold, respectively and metallopro-
teinases Mmp14 and 2 which were elevated by a factor 
of 1.53 and 1.3, respectively. Challenge with ethanol also 
affected cell survival and apoptosis as indicated by ele-
vated expression of Casp7 (1.16 fold change), Card9 (1.64 
fold change), S100a14 (1.29 fold change) and S11a16 
(1.21 fold change). Furthermore, challenge with etha-
nol induced the expression of Pparg, indicating a strong 
metabolic effect. In this experiment, the growth factors 
affected by ethanol were fibroblast growth factor (FGF) 
11 and 9 and insulin growth factor (IGF) 1, whereas HGF 
was expressed, but expression was not induced (data not 
shown). The observed fibrosis was confirmed by induced 
expression of collagen (col) 1a1, which was elevated 
2.26 fold. In summary, expression analysis suggests that 
(See figure on next page.) 
Fig. 2 Inflammation induced by ethanol in NSG mice reconstituted with PBMC from UC patients is characterized by subtypes of monocytes, mac-
rophages, effector memory CD8+ cells and by Mtarc, mTGFß1 and HGF. a Flow cytometric analysis of subtypes of CD14+ monocytes and CD11b+ 
macrophages of human leukocytes isolated from spleens. Unchallenged control group (control), group challenged with 10% ethanol at day 8 and 
50% ethanol at days 15 and 18 (ethanol). For complete data set see Additional file 1: Table S3). Labels given on x-axes on the bottom row apply to 
all charts. b Correlation analysis of effector memory CD8+ T-cells with clinical activity score and Th17 T-cells depicted as scatter blots. Numbers indi-
cate Spearman rank-order correlation coefficients (rho) and p values. Sample sizes: clinical score n = 29, Th17 n = 25. c mRNA expression analysis of 
mTARC, mTGFß1 and HGF depicted as boxplots. Lg-delta CT, logarithmic delta cycle threshold. Boxes represent upper and lower quartiles. Whiskers 
represent variability and outliers are plotted as individual points. For comparison of unchallenged control group versus challenged group, a Student 
T-test was conducted. Labels given on x- and y-axes on the bottom and the side row apply to all charts
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IL-34 is the main cytokine released by epithelial cells to 
induce proliferation and differentiation of monocytes and 
macrophages. This result is in agreement with the previ-
ous observations showing that the predominant effect 
of ethanol challenge was observed with monocytes and 
macrophages.
Design of disease network
Based on the results obtained from the RNAseq analysis 
and the effects of interleukins, chemokines and growth 
factors described in the literature, a disease network was 
designed that might lead to a better understanding of 
inflammatory processes in the NSG-UC model (Fig.  3). 
Whereas IL-7 is a general activator of T cells (Fig. 4), IL-
17c might be responsible for a proinflammatory response 
resulting in increased levels of IL-8, IL-6 and IL-17A 
ultimately leading to increased mucus production and 
attraction of neutrophils (Fig. 5). Lipids released by PLA2 
and presented by CD1a expressing monocytes and mac-
rophages might induce autoimmunity by activation Th1 
(our own results) or Th22 cells (Fig. 6) [6–8]. The inflam-
matory remodeling condition would be the result of the 
Th2 driven inflammation induced by IL-34, TSLP and 
TARC (Figs.  7, 8, 9). In UC patients, this inflammatory 
condition might be responsible for fibrosis and epithelial 
hyperplasia. It is noteworthy that levels of IL-33 which 
has been shown to play a crucial role in atopic derma-
titis [16] are decreased indicating that ILC2 might not 
be drivers of the remodeling condition in the NSG-UC 
(Fig. 10).
As previously suggested, this disease network shows 
two arms of inflammation evoked upon damage of the 
mucosa: A Th1/M1 Tcyt characterized inflammation, 
which we would refer to as acute inflammatory, and a 
Th2/M2 Treg characterized inflammation, which we pre-
viously referred to as the remodeling condition. A patient 
in relapse would most probably exhibit both arms of 
inflammation.
Validation of the disease network in the NSG mouse model
To examine whether the NSG-UC model can be used to 
validate the disease map, two therapeutics were tested, 
which were expected to target crucial immunological 
junctions. PBMC were isolated from patients in relapse. 
NSG mice were reconstituted and challenged according 
to a standard protocol described in “Methods”. Seven 
days post reconstitution the mice were divided into three 
groups: one was left unchallenged, one was challenged 
by rectal application of ethanol plus the respective car-
rier, one was challenged and additionally treated with 
the respective therapeutic. Each group contained four 
animals. Experiments were repeated with two differ-
ent donors in relapse (SCCAI > 5) (for patients baseline 
demographics see Table  1). The response to treatment 
was compared to the control group and the ethanol 
Table 2 Challenge with ethanol resulted in increased 
expression gene associated with inflammation
Sections from distal parts of the colon of NSD mice reconstituted with PBMC 
derived from a patient with UC were challenged with ethanol and subjected 
to RNAseq analysis. Unchallenged control (control, n = 4), group challenged 
with 10% ethanol at day 8, and 50% ethanol at days 15 and 18 (ethanol, n = 4). 
Expression values are depicted as mean total exon read count/mapped reads 
[million] * exon length [kb] (RPKM). The difference between the highest and 
the lowest expression value over all samples (range), inter-quantile rage of 
expression values (IQR), difference between the mean of expression values of 
the ethanol challenged group and the control group, mean expression value of 
ethanol challenged group divided by the mean expression value of the control 
group, FDR corrected p value (EDGE test) (p value)
Feature ID Range IQR Difference Fold change p value
Cytokine
 Il17c 7 2 2.5 11 0.011
 Il1rn 3090 1724 718.75 1.29 0.002
 Il33 712 483 − 347 − 1.98 0.002
 Il34 326 132 81.5 1.44 0.007
 Il7 179 120 39.5 1.20 0.027
 Tgfb1 243 70 63.25 1.45 0.036
 Tnf 100 57 49.25 4.65 2E−07
 Tslp 39 22 10.5 1.39 0.062
Growth factor
 Fgf11 248 71 − 95.75 − 1.65 0.013
 Fgf9 111 83 − 57 − 1.57 0.018
 Igf1 1152 431 412 1.91 1E−04
Phospholipase
 Pla2g10 2170 1285 341.25 1.16 0.039
 Pla2g2f 1314 496 349.75 1.33 0.005
ECM
 Col1a1 11,375 2581 4058 2.26 1E−08
Metalloproteinase
 Mmp14 2092 312 533.5 1.53 0.010
 Mmp2 3247 1104 611.5 1.30 0.045
Cell survival/apoptosis
 Casp7 2691 1749 468 1.16 0.028
 Card9 35 10 9 1.64 0.044
 S100a14 4618 1785 1125.5 1.29 0.002
 S100a16 5359 1594 924 1.21 0.033
Metabolism
 Pparg 1021 374 354 1.54 7E−05
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challenged group (for complete data set, please see Addi-
tional file 1: Tables S4, S5). As observed in previous exper-
iments control animals remained unaffected, whereas in 
all ethanol-challenged groups mice developed the previ-
ously described symptoms and phenotype [11]. At first, 
infliximab was tested, which is supposed to suppress the 
acute arm of inflammation by depletion of TNFα bear-
ing M1 monocytes. However, as suggested by the analy-
sis of inflammatory profiles of human UC patients and 
as predicted by the disease network (Fig. 11) one would 
expect that in mice the remodeling inflammation would 
be retained. As shown in Fig.  13B mice benefited from 
the treatment indicated by the clinical- and histologi-
cal score. Analysis of the histological sections revealed, 
however, fibrotic alterations of the colon architecture 
(Fig.  13Aa). The previously identified acute inflamma-
tory markers CD11b+ CD1a+, CD14+ CD1a+, CD14+ 
CD64+, TARC, HGF and IFNγ diminished, whereas 
expression of TGFß1 was not affected, corroborating the 
histological results (Figs.  14, 15). Infliximab treatment 
also affected M2 monocytes as indicated by a decrease 
of CD14+ CD163+ monocytes, suggesting that the 
fibrotic changes not solely rely on M2 monocytes. These 
results corroborated results from a previous study which 
Fig. 3 Design of disease network based on mRNA expression analysis and effects of cytokines, chemokines and growth factors described in the 
literature. No signal from epithelial cells
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has shown that treatment of patients with infliximab 
induces inflammatory remodeling condition [4]. Next, 
we tested a therapeutic targeting monocytes bearing the 
IL-4 Rα receptor, which is supposed to be predominantly 
expressed on M2 monocytes and Th2 cells. Pitrakinra, 
which has been described as an inhibitor of IL-4Rα/
IL-2Rγ and IL-4Rα/IL-13Rα1 receptor complexes is thus 
supposed to inhibit Th2/M2 directed inflammation with-
out suppressing the Th1/M1. According to the disease 
network, one would expect that NSG-UC mice would not 
benefit from the treatment with pitrakinra (Fig. 12). His-
tological analysis of H&E stained revealed severe damage 
to the colon architecture and influx of inflammatory cells 
(Fig.  13Ab). As shown in Fig.  13B, the clinical- and the 
histological score increased as well as the inflammatory 
markers CD11b+ CD1a+ and IFNγ (Figs.  14, 15) (for 
complete data set see Additional file 1). Mice also exhib-
ited increased expression of TNFα, suggesting that the 
Fig. 4 Design of disease network based on mRNA expression analysis and effects of cytokines, chemokines and growth factors described in the 
literature. Activation of proinflammatory pathway by IL-7
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inflammatory balance is shifted towards a Th1 response. 
The fact that levels of TGFß1 and frequencies of CD14+ 
CD163+ monocytes were decreased supported the 
hypothesis that the remodeling arm of the inflammation 
was suppressed in favor of the acute inflammation. How-
ever, frequencies of CD14+ CD1a+, CD14+ CD64+, 
CD14+ TSLPR+ monocytes were also affected, suggest-
ing that IL-4Rα receptor is more widely expressed fur-
ther corroborating the plasticity of monocytes but also 
suggested that suppressing IL4-Rα1 bearing monocytes is 
not sufficient to suppress symptoms and phenotype.    
Discussion
By now, the NSG-UC model has been proven as a robust 
animal model partially reflective of the human disease. 
Although it has not yet been shown how the toxic effects 
of ethanol translate into inflammation, we hypothesized 
that ethanol damages the mucosal epithelial lining and 
Fig. 5 Design of disease network based on mRNA expression analysis and effects of cytokines, chemokines and growth factors described in the 
literature. Activation of proinflammatory pathway by IL-17c
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thereby induces the release of cytokines, chemokines and 
growth factors to counteract the potential harm accom-
panying the breach of the epithelial lining. The ultimate 
goal of the inflammatory process would thus be to defend 
the organisms against invading pathogens and the resto-
ration of barrier integrity. Hence, the inflammation in the 
NSG-UC model would partially resemble a wound heal-
ing process. Wound healing processes are characterized 
by an influx of neutrophils, macrophages, and mono-
cytes. According to a new concept, macrophages are con-
sidered accessory cell types which support their client 
cells—notabene mucosal epithelial cells in the gut- with 
various functions [36]. Clearance of apoptotic cells is one 
of the major functions of, however, macrophages have 
also the capacity to adapt to the inflammatory milieu 
and to direct to direct inflammation towards inflamma-
tory, healing or regulatory. If our hypothesis is correct, 
one would assume a central role of macrophages and 
monocytes in the NSG-UC model. Although frequencies 
subtypes of T-cells, B-cells and NK T cells were found 
to be elevated in some experiments, these responses 
seemed patient dependent and could not be observed 
in all studies. However, the challenge with ethanol was 
found to profoundly affect monocytes and macrophages. 
Hence, we would define M1-, M2-, and CD1a express-
ing CD14+ monocytes and CD1a expressing CD11b+ 
Fig. 6 Design of disease network based on mRNA expression analysis and effects of cytokines, chemokines and growth factors described in the 
literature. Potential pathway induction by lipids
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macrophages as cell types associated with the ethanol-
induced inflammation. Frequencies of all these cells types 
were highly correlated with the clinical activity-and his-
tological score, however, this observation does not nec-
essarily mean that these cell types cause or add to the 
pathology and phenotype of colitis like symptoms as M2 
monocytes, e.g. are instrumental in controlling inflam-
mation. Challenge with ethanol did not induce further 
maturation of macrophages and monocytes as indicated 
by even levels of CD11b+ CD86+ macrophages and 
CD14+ CD86+ monocytes in the unchallenged versus 
the challenged groups. In addition to macrophages and 
monocytes, a positive correlation was detected between 
effector memory CD8+ cells and the clinical score, cor-
roborating previous results where CD44+ experienced 
T-cells were found to be elevated in the spleen as well as 
Fig. 7 Design of disease network based on mRNA expression analysis and effects of cytokines, chemokines and growth factors described in the 
literature. Activation of remodeling pathway by IL-34
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the colon of NSG-UC mice. This observation suggests 
that the onset of epithelial damage and inflammation 
might also be caused by cytotoxic T-cells. Furthermore, 
frequencies of effector memory CD8+ cells corre-
lated positively with Th17 T-cells, suggesting that these 
cells also play a role in this inflammation. These results 
are in agreement with data obtained from UC patients 
where aberrant expression of circulating Th17, Th1 and 
cytotoxic T-cells was found in patients with UC [5]. The 
most reliable factors associated with the inflammation 
were the chemokine TARC, the cytokine TGFß1 and the 
growth factor HGF, all of which are considered hallmarks 
of wound healing processes [37]. The extent of inflam-
mation was donor-dependent. Patients visiting our clinic 
are in most cases severely diseased and experience a 
chronic continuous form of the disease. A previous study 
has shown (our data) that the majority of these patients 
exhibit high level-expression of autoantibodies directed 
against immune cells indicating that loss or breach of 
tolerance may be one driver in UC. This observation was 
further corroborated by the detection of elevated levels of 
antigen experienced CD44 expressing CD8+ cells colons 
of UC patients as compared to Non-UC donors [4]. This 
observation might explain why the NSG-UC model 
Fig. 8 Design of disease network based on mRNA expression analysis and effects of cytokines, chemokines and growth factors described in the 
literature. Stimulation of remodeling pathway by TSLP
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requires PBMC from UC patients [11] and the positive 
correlation of CD8+ effector memory T-cells with the 
clinical score. NSG mice reconstituted with PBMC from 
healthy subjects did not experience colitis like symptoms 
and phenotype in response to ethanol.
As the previously analyzed factors expressed in the 
colon of NSG mice were selected by the wound heal-
ing hypothesis and hence the selection had a bias, an 
RNAseq analysis was performed. This analysis identified 
IL-7, IL-17c, IL-34 and TSLP as elevated upon challenge 
with ethanol all of which are expressed by epithelial cells. 
Whereas IL-7 is a general activator of T-cells, IL-17c is 
considered to promote inflammation [12–14]. In con-
trast, IL-34 and TSLP are thought to favor a remodeling 
of the colon architecture [18, 23, 24]. Also, phospholipase 
A2 was found to be elevated, suggesting that lipids pre-
sented by CD1a might also provoke inflammation. Rather 
unexpectedly, IL-33 levels were found to be decreased, 
indicating that a prominent route leading to remodeling 
is lacking in this model. Based on these results, the RT-
PCR analysis from distal parts of the colon and mode of 
action of various cell types, chemokines, cytokines and 
factors described in the literature a disease network was 
designed. Highlighting various routes of inflammation 
Fig. 9 Design of disease network based on mRNA expression analysis and effects of cytokines, chemokines and growth factors described in the 
literature. Attraction and stimulation of remodeling pathway by TARC
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induced by different cytokines, chemokines and lipids 
corroborated the previous findings that at least two 
inflammatory conditions prevail: a proinflammatory or 
acute condition and a remodeling condition. In a healthy 
organism, the acute inflammatory condition would 
ensure the protection against invading pathogens. In UC 
patients, the cause of the proinflammatory condition 
still remains to be elucidated. One possible explanation 
is that a breach of the epithelial lining leads to influx of 
bacteria into the mucosa. Alternatively, a general loss of 
tolerance towards the microbiota and the self-antigens 
might shift the intestinal immunological equilibrium. 
Our results suggest that there could be at least two driv-
ers of the acute inflammatory process: IL-17c and CD1a 
expressing monocytes. In wound healing processes this 
equilibrium would be regained by restoring the integ-
rity of the epithelial barrier and by mechanism to resolve 
inflammation. Our observations suggest that fibrosis in 
UC patients is the result of an ongoing restoration pro-
cess to heal the destruction induced by the proinflamma-
tory response. To understand the disturbed inflammatory 
balance future research has to examine why some UC 
patients have the capacity to control inflammation and 
experience times of remission while others do not.
Fig. 10 Design of disease network based on mRNA expression analysis and effects of cytokines, chemokines and growth factors described in the 
literature. Activation of remodeling pathway by IL-33
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Both types of inflammation would be expected to be 
induced upon challenge with ethanol in the NSG-UC 
mouse model. To validate this disease network, two dif-
ferent therapeutic to affect M1 or M2 macrophages were 
tested in the NSG-UC model. In a previous study, inflixi-
mab had been shown to induce a remodeling condition 
in UC patients [4]. The responses to infliximab in the 
NSG-UC model partially reflected this condition. Mice 
responded to treatment with decreased clinical activity 
and decreased frequencies of CD14+ monocytes, sug-
gesting that not only M1 monocytes bear surface TNFα. 
Factors associated with inflammation such as TARC-, 
HGF- and INFγ mRNA decreased, whereas TGFß1 
mRNA levels were not affected, suggesting an ongoing 
remodeling of the colon. This observation was corrobo-
rated by histological analysis that displayed less influx 
of inflammatory cells but retained fibrosis. Pitrakinra is 
also supposed to act on monocytes; in this case, how-
ever, monocytes bearing the IL-4Rα/IL-13Rα1 receptor 
complex would be targeted. Also, pitrakinra has been 
shown to suppress the differentiation of Th2 cells which 
carry the IL4-Rα/IL2Rγ chain. As observed when mice 
were treated with infliximab all subtypes of monocytes 
were affected, in this case, however, an increase of the 
CD1a expressing CD11b+ macrophage was observed. 
The increased clinical- and histological score increased 
Fig. 11 Design of disease network based on mRNA expression analysis and effects of cytokines, chemokines and growth factors described in the 
literature. Blockade of TNFα leads to inhibition of the proinflammatory pathway whereas the remodeling pathway remains unaffected
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levels of IFNγ and TNFα suggested that inflammation 
was completely shifted towards a Th1 phenotype, sup-
pressing the remodeling arm of the inflammation.
Obviously, the disease network presented in this study 
is still too simple to completely describe the inflamma-
tory dynamic underlying the pathology of UC. It does 
not yet include important aspects promoting inflam-
mation as the role of B-cells, mast cells, basophils and 
eosinophils and the high plasticity of T-cells. It also does 
not yet account for concentration levels of cytokines, 
chemokines and growth factors and their cognate 
receptors. Hence, it is a first approach to portray inflam-
mation in UC as a mobilée, in which the entire balance 
can be shifted when single cell types are depleted or pro-
moted. It also suggests that it is not as simple to frame a 
certain cell type or cytokine to cause pathology based on 
the mere fact that frequencies or levels are elevated. Our 
model might explain why anrukinzumab, an anti-IL-13 
monoclonal antibody was found to not affect clinical 
activity score, mucosal healing, rectal bleeding or clinical 
remission rates [38]. Conversely, it might explain why inf-
liximab is contraindicated in patients with stenosis. Thus, 
Fig. 12 Design of disease network based on mRNA expression analysis and effects of cytokines, chemokines and growth factors described in the 
literature. Blockade of IL-4Rα1 receptor leads to inhibition of the remodeling pathway and promotes the proinflammatory pathway
(See figure on next page.) 
Fig. 13 Treatment infliximab or pitrakinra had different effects in NSG mice reconstituted with PBMC from UC patients. A Photomicrographs of 
H&E-stained sections of distal parts of the colon from mice that had been reconstituted with PBMC from patients with UC, challenged with ethanol 
and treated with a infliximab, b pitrakinra. Mice were treated by intraperitoneal application of pitrkinra on days 7–9 and 14–21 and PBS were used 
as carrier control. Infliximab was applied by intraperitoneal injection on day 7, 14, 17 and isotype was used as a control. Arrows indicate edema and 
influx of inflammatory cells. B Depiction of clinical- and histological score as boxplots. Boxes represent upper and lower quartiles, whiskers repre-
sent variability and outliers are plotted as individual points. Unchallenged control (control), challenged control (ethanol + PBS/isotype), challenged 
and treated (ethanol + infliximab/pitrakinra). For comparison of groups ANOVA followed by TukeyHSD was conducted. Labels given on y-axes on 
the bottom apply to all charts
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every therapeutic can shift the balance and might have to 
be complemented with another therapeutic to reach full 
response. In the future, more comprehensive studies have 
to be performed to improve our knowledge of disease 
networks and the dynamics underlying inflammation in 
UC.
Obviously, the inadequacy to fully reflect the human 
disease also applies to the NSG-UC model. So far, it 
disregards the influence of basophils, mast cells, and 
eosinophils. Also, one has to keep in mind that it is a 
chimeric model and that some of the chemokines and 
cytokines do not exert their activity on receptors of the 
other species as it has been shown for IL-4 and TSLP [39, 
40]. Thus, this model has to be improved in future studies 
to analyze the involvement of T-cells, B-cells basophils, 
eosinophils and mast cells. However, it seems to reflect 
Fig. 14 Treatment infliximab or pitrakinra had different effects in NSG mice reconstituted with PBMC from UC patients. Flow cytometric analysis 
of frequencies of subtypes of CD11b+ macrophages and CD14+ monocytes depicted as boxplots. Mice were treated as described in Fig. 13. For 
complete data set see Additional file 1: Tables S4, S5). Boxes represent upper and lower quartiles, whiskers represent variability and outliers are plot-
ted as individual points. Unchallenged control (control), challenged control (ethanol + PBS/isotype), challenged and treated (ethanol + infliximab/
pitrakinra). For comparison of groups ANOVA followed by TukeyHSD was conducted. Labels given on x- and y-axes on the bottom and the side row 
apply to all charts
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Fig. 15 Treatment infliximab or pitrakinra had different effects in NSG 
mice reconstituted with PBMC from UC patients. mRNA expression 
levels of TGFß1, HGF, TARC, IFNγ and TNFa as boxplots. Mice were 
treated as described in Fig. 13. For complete data set see Additional 
file 1: Tables S4, S5). Lg-delta CT, logarithmic delta cycle threshold. 
Boxes represent upper and lower quartiles, whiskers represent vari-
ability and outliers are plotted as individual points. Unchallenged 
control (control), challenged control (ethanol + PBS/isotype), chal-
lenged and treated (ethanol + infliximab/pitrakinra). For comparison 
of groups ANOVA followed by TukeyHSD was conducted. Labels 
given on x- and y-axes on the bottom and the side row apply to all 
charts
◂
the autoimmune aspect of the disease and can be used to 
validate therapeutics and hypothesis.
Conclusions
The combination of patient profiling, the design of a dis-
ease network helps and the NSG-UC animal model may 
help to get a better understanding of the inflammatory 
processes in UC and may ultimately lead to individual-
ized and phase dependent therapies.
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